Compare iShares MSCI ACWI ETF (ACWI) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Adaptive Biotechnologies Corp — how do they compare? iShares MSCI ACWI ETF trades at $161.72, while Adaptive Biotechnologies Corp trades at $25.57 (market cap $4.04B). Which is the better fit depends on your goals.
| ACWI | ADPT | |
|---|---|---|
52-Week High | $161.44 | $25.45 |
52-Week Low | $132.04 | $12.30 |
Market Cap | — | $4.04B |
Sector | — | Health |
Enterprise Value | — | $4.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
